Prasinezumab

Roche's Phase IIb PADOVA study of prasinezumab, an investigational mAb for early-stage Parkinson’s disease, missed the primary endpoint but showed potential efficacy, particularly in levodopa-treated patients. Prasinezumab was well-tolerated, with no new safety signals. Roche and Prothena aim to develop disease-modifying treatments targeting α-synuclein.

Prasinezumab, an investigational monoclonal antibody, did not achieve statistical significance for the primary endpoint in the Phase IIb PADOVA trial for early-stage Parkinson disease. However, it showed potential efficacy with a numerical delay in motor progression and positive trends across multiple secondary and exploratory endpoints. The drug targets α-syn protein buildup to inhibit PD progression and is under evaluation in ongoing trials.

Roche's phase IIb PADOVA study of prasinezumab in early-stage Parkinson’s disease showed numerical delay in motor progression and positive trends on multiple endpoints, with no new safety signals. Prasinezumab, targeting a-syn aggregates, continues to be evaluated in ongoing studies.

Roche's experimental Parkinson’s drug, prasinezumab, failed another key trial but shows potential in levodopa users, prompting further exploration. Despite mixed results, Roche plans continued studies and data evaluation.

Roche and Prothena's prasinezumab, targeting alpha-synuclein for Parkinson's, missed primary endpoint in phase 2b PADOVA trial but showed numerical delay in motor progression and positive trends on secondary endpoints. Roche plans further exploration and collaboration with Parkinson's community.

The PADOVA study showed potential delay in motor progression and positive trends on secondary endpoints for prasinezumab in early-stage Parkinson's disease, with no new safety signals. Roche will evaluate data and collaborate with health authorities to determine next steps.

Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease missed its primary endpoint but showed potential clinical benefits, particularly in levodopa-treated patients, with a favorable safety profile.

Prothena's Phase IIb study of prasinezumab in early-stage Parkinson’s patients showed some success in primary endpoint but fell short of expectations. The drug was more effective in levodopa-treated patients and well-tolerated. Prothena and Roche will analyze data for potential disease-modifying treatment.

Genentech's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson’s disease showed potential efficacy with HR=0.84 [0.69-1.01] and p=0.0657, missing statistical significance. The drug was more effective in those on levodopa, HR=0.79 [0.63-0.99]. Positive trends were observed across secondary endpoints, and prasinezumab was well-tolerated. Further studies are ongoing.

High-profile dementia researchers, including Eliezer Masliah, have been accused of fraud, influencing neurological research and drug trials. Dr. Matthew Schrag, a neurologist, investigates such misconduct, emphasizing the need for research integrity and high-quality data. Schrag highlights the challenges in spotting fraud and the ethical concerns of running trials based on potentially fraudulent data, advocating for a broader approach to Alzheimer's research beyond the amyloid hypothesis.